813 related articles for article (PubMed ID: 29857816)
1. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
Stiewe T; Haran TE
Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
[TBL] [Abstract][Full Text] [Related]
2. Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity.
Xu J; Wang J; Hu Y; Qian J; Xu B; Chen H; Zou W; Fang JY
Cell Death Dis; 2014 Mar; 5(3):e1108. PubMed ID: 24603336
[TBL] [Abstract][Full Text] [Related]
3. The role of p53 in cancer drug resistance and targeted chemotherapy.
Hientz K; Mohr A; Bhakta-Guha D; Efferth T
Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
5. SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic marker.
Kolukula VK; Sahu G; Wellstein A; Rodriguez OC; Preet A; Iacobazzi V; D'Orazi G; Albanese C; Palmieri F; Avantaggiati ML
Oncotarget; 2014 Mar; 5(5):1212-25. PubMed ID: 24681808
[TBL] [Abstract][Full Text] [Related]
6. Changing mutational and adaptive landscapes and the genesis of cancer.
Liggett LA; DeGregori J
Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):84-94. PubMed ID: 28167050
[TBL] [Abstract][Full Text] [Related]
7. Should mutant TP53 be targeted for cancer therapy?
Wang Z; Strasser A; Kelly GL
Cell Death Differ; 2022 May; 29(5):911-920. PubMed ID: 35332311
[TBL] [Abstract][Full Text] [Related]
8. Prion-like aggregation of mutant p53 in cancer.
Silva JL; De Moura Gallo CV; Costa DC; Rangel LP
Trends Biochem Sci; 2014 Jun; 39(6):260-7. PubMed ID: 24775734
[TBL] [Abstract][Full Text] [Related]
9. p53 gain-of-function mutations increase Cdc7-dependent replication initiation.
Datta A; Ghatak D; Das S; Banerjee T; Paul A; Butti R; Gorain M; Ghuwalewala S; Roychowdhury A; Alam SK; Das P; Chatterjee R; Dasgupta M; Panda CK; Kundu GC; Roychoudhury S
EMBO Rep; 2017 Nov; 18(11):2030-2050. PubMed ID: 28887320
[TBL] [Abstract][Full Text] [Related]
10. Mutant p53 partners in crime.
Kim MP; Lozano G
Cell Death Differ; 2018 Jan; 25(1):161-168. PubMed ID: 29099488
[TBL] [Abstract][Full Text] [Related]
11. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf
Chapeau EA; Gembarska A; Durand EY; Mandon E; Estadieu C; Romanet V; Wiesmann M; Tiedt R; Lehar J; de Weck A; Rad R; Barys L; Jeay S; Ferretti S; Kauffmann A; Sutter E; Grevot A; Moulin P; Murakami M; Sellers WR; Hofmann F; Jensen MR
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3151-3156. PubMed ID: 28265066
[TBL] [Abstract][Full Text] [Related]
12. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration.
Yeudall WA; Vaughan CA; Miyazaki H; Ramamoorthy M; Choi MY; Chapman CG; Wang H; Black E; Bulysheva AA; Deb SP; Windle B; Deb S
Carcinogenesis; 2012 Feb; 33(2):442-51. PubMed ID: 22114072
[TBL] [Abstract][Full Text] [Related]
13. Gain-of-Function Mutant p53: All the Roads Lead to Tumorigenesis.
Stein Y; Rotter V; Aloni-Grinstein R
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817996
[TBL] [Abstract][Full Text] [Related]
14. When Genome Maintenance Goes Badly Awry.
Kass EM; Moynahan ME; Jasin M
Mol Cell; 2016 Jun; 62(5):777-87. PubMed ID: 27259208
[TBL] [Abstract][Full Text] [Related]
15. Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo.
Xiong S; Chachad D; Zhang Y; Gencel-Augusto J; Sirito M; Pant V; Yang P; Sun C; Chau G; Qi Y; Su X; Whitley EM; El-Naggar AK; Lozano G
Cancer Res; 2022 May; 82(10):1926-1936. PubMed ID: 35320355
[TBL] [Abstract][Full Text] [Related]
16. Mathematical models of cell phenotype regulation and reprogramming: Make cancer cells sensitive again!
Wooten DJ; Quaranta V
Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):167-175. PubMed ID: 28396217
[TBL] [Abstract][Full Text] [Related]
17. Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression.
Yue X; Zhang C; Zhao Y; Liu J; Lin AW; Tan VM; Drake JM; Liu L; Boateng MN; Li J; Feng Z; Hu W
Genes Dev; 2017 Aug; 31(16):1641-1654. PubMed ID: 28947497
[TBL] [Abstract][Full Text] [Related]
18. Induction of genetic instability by gain-of-function p53 cancer mutants.
Xu Y
Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
[TBL] [Abstract][Full Text] [Related]
19. Chaperoning the guardian of the genome. The two-faced role of molecular chaperones in p53 tumor suppressor action.
Wawrzynow B; Zylicz A; Zylicz M
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):161-174. PubMed ID: 29355591
[TBL] [Abstract][Full Text] [Related]
20. Structural biology of the tumor suppressor p53 and cancer-associated mutants.
Joerger AC; Fersht AR
Adv Cancer Res; 2007; 97():1-23. PubMed ID: 17419939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
